ASXL1 truncating mutations drive leukemic resistance to T cell attack
Dustin McCurry, Zhongqi Ge, Jaehyun Lee…·Pavan Bachireddy
This study identifies ASXL1 truncating mutations as a driver of leukemic resistance to T cell attack and proposes EZH2 inhibition as a therapeutic strategy to overcome this resistance.